PE20021067A1 - USE OF NK3 RECEIVER ANTAGONISTS - Google Patents
USE OF NK3 RECEIVER ANTAGONISTSInfo
- Publication number
- PE20021067A1 PE20021067A1 PE2002000415A PE2002000415A PE20021067A1 PE 20021067 A1 PE20021067 A1 PE 20021067A1 PE 2002000415 A PE2002000415 A PE 2002000415A PE 2002000415 A PE2002000415 A PE 2002000415A PE 20021067 A1 PE20021067 A1 PE 20021067A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- aryl
- functional
- candle7
- cycloalkylalkyl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 206010000060 Abdominal distension Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 150000003973 alkyl amines Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001351 cycling effect Effects 0.000 abstract 1
- 201000000117 functional diarrhea Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIERE A UN METODO PARA EL TRATAMIENTO DE SINDROME DEL INTESTINO IRRITABLE, DISTENSION ABDOMINAL FUNCIONAL, ESTRENIMIENTO FUNCIONAL, DIARREA FUNCIONAL QUE COMPRENDE LA ADMINISTRACION DE UN ANTAGONISTA DEL RECEPTOR NEUROQUININA B NK3 DE FORMULA I, DONDE Ar ES FENILO, NAFTILO, CICLOALCADIENILO C5-C7, HETEROCICLO; R ES ALQUILO C1-C8, CICLOALQUILO C3-C7, CICLOALQUILALQUILO C4-C7, FENILO, FENILALQUILO C1-C6, ENTRE OTROS; R1 Y R2 SON H, ALQUILO C1-C6 O JUNTOS FORMAN UN GRUPO (CH2)n; n ES 3-5 O R1 Y R FORMAN JUNTOS (CH2)q; q ES 2-5; R3 Y R4 SON H, ALQUILO C1-C6, ALQUENILO C1-C6, ARILO, ALCOXI C1-C6, HIDROXI, HALOGENO, O FORMAN UN GRUPO a, b, ENTRE OTROS; V Y V1 SON H, O; u ES 0-2; O(CH2)sOW; S ES 2-4; W ES H, ALQUILO C1-C6, HIDROXIALQUILO, ALQUILAMINO; O R4 ES (CH2)t CUANDO SE CICLA CON R5 COMO ARILO; t ES 1-3; R5 ES ALQUILO C1-C6, CICLOALQUILO C3-C7, CICLOALQUILALQUILO C4-C7, ARILO, HETEROCICLO; X ES O, S, N-CºN. SON COMPUESTOS PREFERIDOS (S)-N-(O-ETILBENCIL)-3-HIDROXI-2-FENILQUINOLINA-4-CARBOXAMIDA; [[(DICLOROFENIL)(TRIMETEOXIBENZOIL)MORFOLINIL]ETILESPIRO[BENZO(c)TIOFENOPIPERIDINA]REFERS TO A METHOD FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME, FUNCTIONAL ABDOMINAL DISTENSION, FUNCTIONAL STRENGTH, FUNCTIONAL DIARRHEA, INCLUDING THE ADMINISTRATION OF AN ANTAGONIST OF THE RECEPTOR NEUROQUININE B NK3 DE FORMILONIUS CANDYLUS 7, CANDYLONIUS CANDLE7, CANDYLONIC NAPHILUS I7, CANDYLONICLE I5 CANDYLENE CANDLE7 , HETEROCICLO; R IS C1-C8 ALKYL, C3-C7 CYCLOALKYL, C4-C7 CYCLOALKYLALKYL, PHENYL, C1-C6 PHENYLALKYL, AMONG OTHERS; R1 AND R2 ARE H, C1-C6 ALKYL OR TOGETHER FORM A (CH2) n GROUP; n IS 3-5 OR R1 AND R FORM TOGETHER (CH2) q; q IS 2-5; R3 AND R4 ARE H, C1-C6 ALKYL, C1-C6 ALKYL, ARYL, C1-C6 ALCOXY, HYDROXY, HALOGEN, OR FORM A GROUP a, b, AMONG OTHERS; V AND V1 ARE H, O; u ES 0-2; O (CH2) sOW; S IS 2-4; W IS H, C1-C6 ALKYL, HYDROXYALKYL, ALKYLAMINE; OR R4 IS (CH2) t WHEN CYCLING WITH R5 AS ARYL; t IS 1-3; R5 IS C1-C6 ALKYL, C3-C7 CYCLOALKYL, C4-C7 CYCLOALKYLALKYL, ARYL, HETEROCYCLE; X IS O, S, N-CºN. PREFERRED COMPOUNDS ARE (S) -N- (O-ETHYLBENZYL) -3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE; [[(DICHLOROPHENIL) (TRIMETEOXIBENZOIL) MORFOLINYL] ETHYLSPIRO [BENZO (c) THIOPHENOPIPERIDINA]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0112208A GB0112208D0 (en) | 2001-05-18 | 2001-05-18 | New use |
| GB0129268A GB0129268D0 (en) | 2001-12-06 | 2001-12-06 | Novel use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20021067A1 true PE20021067A1 (en) | 2003-02-02 |
Family
ID=26246093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000415A PE20021067A1 (en) | 2001-05-18 | 2002-05-17 | USE OF NK3 RECEIVER ANTAGONISTS |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1387687A4 (en) |
| JP (1) | JP2004534761A (en) |
| KR (1) | KR20040016865A (en) |
| CN (1) | CN1269483C (en) |
| AR (1) | AR045879A1 (en) |
| AU (1) | AU2002303811B2 (en) |
| BR (1) | BR0209662A (en) |
| CA (1) | CA2447063A1 (en) |
| CZ (1) | CZ20033115A3 (en) |
| HU (1) | HUP0400966A2 (en) |
| IL (1) | IL158701A0 (en) |
| MX (1) | MXPA03010509A (en) |
| MY (1) | MY134211A (en) |
| NO (1) | NO20035121L (en) |
| NZ (1) | NZ529462A (en) |
| PE (1) | PE20021067A1 (en) |
| PL (1) | PL367308A1 (en) |
| TW (1) | TWI243678B (en) |
| WO (1) | WO2002094187A2 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| BR122018074353B8 (en) | 2003-01-28 | 2023-05-02 | Ironwood Pharmaceuticals Inc | pharmaceutical composition, polypeptide and methods for producing them |
| ATE387189T1 (en) * | 2004-03-30 | 2008-03-15 | Smithkline Beecham Corp | SPRAY DRIED PHARMACEUTICAL COMPOSITIONS |
| WO2005100997A2 (en) * | 2004-04-16 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3) |
| WO2007041479A2 (en) * | 2005-09-30 | 2007-04-12 | Smithkline Beecham Corporation | Pharmaceutical compositions |
| TW201018662A (en) | 2005-12-12 | 2010-05-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
| ES2559319T3 (en) | 2007-06-04 | 2016-02-11 | Synergy Pharmaceuticals Inc. | Guanylate cliclas agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2384318B1 (en) | 2008-12-31 | 2017-11-15 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| KR200452372Y1 (en) * | 2010-05-14 | 2011-02-22 | 서일수 | Communication line support device of construction lift |
| KR101034774B1 (en) * | 2010-07-30 | 2011-05-17 | (주)챔피온코리아 | Lift device using wire rope |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| HK1211469A1 (en) | 2012-08-21 | 2016-05-27 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| AU2014250956B2 (en) | 2013-04-12 | 2019-04-04 | Ardelyx, Inc. | NHE3-binding compounds and methods for inhibiting phosphate transport |
| EP2986293A1 (en) | 2013-04-19 | 2016-02-24 | Astrazeneca AB | A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) |
| EA201592263A1 (en) | 2013-06-05 | 2016-05-31 | Синерджи Фармасьютикалз, Инк. | ULTRASCULAR AGONISTS OF GUANYLACYCLASE C, METHOD OF THEIR RECEIVING AND USING |
| WO2018129557A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
| WO2018129552A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2719311B1 (en) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Compounds that are selective antagonists of the human NK3 receptor and their use as drugs and diagnostic tools. |
| US5434158A (en) * | 1994-04-26 | 1995-07-18 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin-3 antagonists |
| AR004735A1 (en) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT. |
| JP2002500645A (en) * | 1997-05-23 | 2002-01-08 | スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ | Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists |
| AR021355A1 (en) * | 1998-11-20 | 2002-07-17 | Smithkline Beecham Spa | DERIVATIVES OF QUINOLINA. PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE |
-
2002
- 2002-05-16 MY MYPI20021787A patent/MY134211A/en unknown
- 2002-05-17 BR BR0209662-5A patent/BR0209662A/en not_active IP Right Cessation
- 2002-05-17 PE PE2002000415A patent/PE20021067A1/en not_active Application Discontinuation
- 2002-05-17 AR ARP020101845A patent/AR045879A1/en not_active Application Discontinuation
- 2002-05-17 AU AU2002303811A patent/AU2002303811B2/en not_active Ceased
- 2002-05-17 CA CA002447063A patent/CA2447063A1/en not_active Abandoned
- 2002-05-17 JP JP2002590908A patent/JP2004534761A/en active Pending
- 2002-05-17 EP EP02731870A patent/EP1387687A4/en not_active Withdrawn
- 2002-05-17 PL PL02367308A patent/PL367308A1/en not_active Application Discontinuation
- 2002-05-17 CN CNB028101588A patent/CN1269483C/en not_active Expired - Fee Related
- 2002-05-17 HU HU0400966A patent/HUP0400966A2/en unknown
- 2002-05-17 NZ NZ529462A patent/NZ529462A/en unknown
- 2002-05-17 KR KR10-2003-7014960A patent/KR20040016865A/en not_active Withdrawn
- 2002-05-17 WO PCT/US2002/015911 patent/WO2002094187A2/en not_active Ceased
- 2002-05-17 IL IL15870102A patent/IL158701A0/en unknown
- 2002-05-17 MX MXPA03010509A patent/MXPA03010509A/en not_active Application Discontinuation
- 2002-05-17 TW TW091110318A patent/TWI243678B/en active
- 2002-05-17 CZ CZ20033115A patent/CZ20033115A3/en unknown
-
2003
- 2003-11-17 NO NO20035121A patent/NO20035121L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20033115A3 (en) | 2004-09-15 |
| PL367308A1 (en) | 2005-02-21 |
| MXPA03010509A (en) | 2004-03-02 |
| TWI243678B (en) | 2005-11-21 |
| EP1387687A2 (en) | 2004-02-11 |
| AR045879A1 (en) | 2005-11-16 |
| IL158701A0 (en) | 2004-05-12 |
| HUP0400966A2 (en) | 2004-08-30 |
| JP2004534761A (en) | 2004-11-18 |
| EP1387687A4 (en) | 2006-07-05 |
| CN1509175A (en) | 2004-06-30 |
| WO2002094187A2 (en) | 2002-11-28 |
| BR0209662A (en) | 2004-04-20 |
| MY134211A (en) | 2007-11-30 |
| AU2002303811B2 (en) | 2005-07-07 |
| WO2002094187A3 (en) | 2003-05-30 |
| KR20040016865A (en) | 2004-02-25 |
| NO20035121D0 (en) | 2003-11-17 |
| CN1269483C (en) | 2006-08-16 |
| NZ529462A (en) | 2005-07-29 |
| CA2447063A1 (en) | 2002-11-28 |
| NO20035121L (en) | 2003-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20021067A1 (en) | USE OF NK3 RECEIVER ANTAGONISTS | |
| PE34096A1 (en) | TRICYCLIC DERIVATIVE OF PYRAZOLE | |
| AR061486A1 (en) | DERIVATIVES OF 2-PIRAZINACARBOXAMIDA | |
| PE20030848A1 (en) | SPIROPIPERIDINE N-SUBSTITUTED COMPOUNDS AS LIGANDS FOR THE ENT-1 RECEPTOR | |
| PE20030847A1 (en) | AZA-ARILPIPERAZINES AS LIGANDS OF THE 5HT2 RECEPTOR | |
| PE20081152A1 (en) | N-SUBSTITUTED AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | |
| PE20050874A1 (en) | BENZHIMIDAZOLONE COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE 5-HT4 RECEPTOR | |
| PE20091884A1 (en) | SELECTED CGRP ANTAGONISTS, PROCEDURE FOR THEIR PREPARATION, AS WELL AS THEIR USE AS A MEDICINE | |
| PE20040935A1 (en) | 2-QUINAZOLINE SUBSTITUTE-4-ILAMINE ANALOGS AS MODULATORS OF CAPSAICIN RECEPTORS | |
| PE20040720A1 (en) | BENZODIOXOL DERIVATIVES | |
| PE109598A1 (en) | CONDENSED PYROLCARBOXAMIDES USEFUL AS GABA BRAIN RECEPTOR LEAGUES | |
| PE20050465A1 (en) | QUINUCLIDINE DERIVED COMPOUNDS AS ANTAGONISTS OF THE MUSCARINE M3 RECEPTOR | |
| PE20001467A1 (en) | DERIVATIVES OF 4-PHENYLPYRIDINE AS ANTAGONISTS OF THE NEUROQUININ RECEPTOR | |
| PE20021155A1 (en) | QUINOLINE DERIVATIVES AS ANTAGONISTS OF NEUROPEPTIDES AND | |
| PE20010854A1 (en) | USE OF SUBSTITUTED PYRIMIDINE 4 DERIVATIVES AS ANTAGONISTS OF GLUTAMATE mGluR1 RECEPTORS | |
| PE20050525A1 (en) | SUBSTITUTED PIRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS ANTAGONISTS OF THE BRADIQUININ B1 RECEPTOR | |
| PE20010600A1 (en) | DERIVATIVES OF BENZHIMIDAZOLONES HAVING AFFINITY FOR MIXED RECEPTORS OF SEROTONIN AND DOPAMINE | |
| PE20020298A1 (en) | DERIVATIVES OF 1,3,8-TRIAZA-SPIRO [4,5] DECAN-4-ONA AS ANTAGONISTS OF NEUROQUININ NK-1 RECEPTORS | |
| PE20021094A1 (en) | SUBSTITUTE CYCLOHEXANE-1,4-DIAMINE DERIVATIVES | |
| PE20060531A1 (en) | DERIVATIVES OF PYRIDAZIN-3- (2H) -ONE AS INHIBITORS OF PHOSPHODIESTERASE 4 | |
| PE20011119A1 (en) | ESTROGEN AGONIST / ANTAGONIST PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RESPONDING TO AN INCREASE IN TESTOSTERONE | |
| PE20030257A1 (en) | 8-AZA-11-DEOXY-PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS | |
| PE20050132A1 (en) | SUBSTITUTED HETEROCYCLIC PIPERAZINES | |
| ES2148227T3 (en) | DERIVATIVES OF 1-PIPERAZINO-1,2-DIHIDROINDENO. | |
| PE20050420A1 (en) | PHENACILO 2-HYDROXY-3-DIAMINOALKANOS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |